By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1799  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.

We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.

As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.

At Amgen, we believe in the power of tomorrow and it shows.

Discover what Amgen can do for you by visiting

For more information, visit, LinkedIn and follow us on


Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 20,000
Symbol: AMGN

Company News
Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts 9/25/2017 9:45:30 AM
5 Reasons Amgen (AMGN)'s Neulasta Biosimilar Might Not Win Approval 9/25/2017 6:42:36 AM
Amgen (AMGN)'s Big Influence On New And Old Biotechs In SoCal 9/21/2017 6:26:42 AM
Amgen (AMGN) Could Rally Higher On This Breakout 9/18/2017 6:15:02 AM
Amgen (AMGN) Release: New FOURIER Analysis Shows Repatha (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes 9/15/2017 9:16:16 AM
Amgen (AMGN), Allergan (AGN) Make History With First Cancer Biosimilar OK—Will Take on Genentech (RHHBY)'s $6 Billion Best-Seller 9/15/2017 5:40:14 AM
Amgen (AMGN) Highlights The Latest EVENITY (Romosozumab) And Prolia (Denosumab) Research At American Society for Bone and Mineral Research Annual Meeting 9/12/2017 11:46:43 AM
Amgen (AMGN) Release: EVENITY (romosozumab) ARCH Study Results Published In The New England Journal of Medicine 9/12/2017 7:04:22 AM
Amgen (AMGN) And Allergan (AGN) Present Phase III Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress 9/11/2017 6:26:07 AM
Amgen (AMGN) Release: New Data Demonstrate Aimovig (Erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies 9/8/2017 7:33:12 AM